// App-Quantinova.ai

138 : Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study

Researchers

Presenter

  • Franco Locatelli

Principal Investigators

  • Maura Faraci

  • Ibrahim Yakoub-Agha

  • Stephane Girault

  • Kate Wheeler

  • Robert J. Ryan

  • Raj Hanvesakul

  • Mohamad Mohty

Medical Centers

  • Department of Pediatric Hematology and Oncology,IRCCS Bambino Gesù Children's Hospital, Sapienza University of Rome,Rome,Italie

  • Istituto Giannina Gaslini, Genoa, Italy

  • CHU de Lille, Univ Lille, INSERM U1286, Infinite,Lille,France

  • Hematologie Clinique et Therapie Cellulaire, Limoges, France

  • Paediatric Oncology, Oxford Children’s Hospital, Oxford, United Kingdom

  • Merck Pharmaceuticals, Philadelphia, PA

  • Jazz Pharmaceuticals,Oxford,United Kingdom

  • Hôpital St Antoine, Sorbonne University, INSERM UMRs 938, Paris, France

Locations

  • Italy

  • France

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatic veno-occlusive disease with immunodeficiency

  • Gastrointestinal bleeding

  • Hyperbilirubinemia

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • Defibrotide

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT03032016

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved